ABO and Alzheimer disease: Based on our work with human iPSC-derived neurons, it is likely that these mutations in ADAM10 will also lead to increased cell surface PrPC and enhanced AβO binding and cytotoxicity, which may contribute to the AD phenotype in individuals with such ADAM10 mutations.